An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally.
VERDICT
The label
Distribution
read at $10.72
Perrigo Company plc holds its Distribution at $10.72.
PHPhase · the trend structure carries the Distribution label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 62 days
Price
$10.72
Valuation
N/A trailing · 4.54 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.52
OPPORTUNITY
The opportunity · what the numbers say it is worth
Read at
$10.72
N/A P/E · 4.54 fwd
Our fair value
$18.63
74% discount
Analyst target (avg)
$16.00
+49% to current
Target low $14.00Analyst target rangeTarget high $20.00
▲ current $10.72 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$10.72
you are here
Conservative
$18.63
+74%
Analyst avg
$16.00
+49%
Our fair value
$18.63
+74%
Analyst high
$20.00
+87%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
-7.20%
Profit margin
-43.50%
Debt to equity
153.22
Analyst consensus
None · 4 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
It depends which standard you follow. There are two widely recognised ways to check whether a company is suitable for a Muslim investor, and on this company they disagree. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✗ DOES NOT PASS
Our stricter standard· asset-based The one Titan applies✓ PASSES
Why the two disagree. They fall out over one thing only: the company’s debt. Our stricter standard measures that debt against what the company owns, and it works out too high to pass. The common standard measures the same debt against what the company is worth on the stock market, where it works out low enough to pass. Every other check, the two agree on. So in practice, most halal apps would treat this as fine to hold, while our stricter view would not — and which line you follow is between you and your scholar.
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is of its assets, above the one-third ceiling the screen allows. Against market value it is 258.1%, under the 30% line the market-value standard uses — so that standard clears it.Divergent
Interest-bearing cashInterest-bearing cash and securities are of assets, above the one-third limit.Fail
ReceivablesMoney owed to the company is of assets, above the 49% limit.Fail
Revenue purityOnly 0.0% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Cheap label on a business losing ground
Pick up a packet of paracetamol or a cough remedy at the chemist and the odds are decent it comes from Perrigo's factories. Yet the numbers tell a different story. Revenue is shrinking at seven percent a year, margins have collapsed to minus forty four percent and return on equity sits at minus fifty two percent, so the apparent seventy four percent margin of safety at ten dollars seventy two simply reflects a firm that is eating itself.
We pass because a forward multiple of four point five times cannot disguise the absence of growth or any visible moat. Four analysts see a median target of sixteen dollars but offer no consensus rating, which matches our own view that this is not an opportunity. The ethical screen is cleared, yet clean governance does not fix a business that is contracting.
The real risk sits in the assumption that losses will turn around without visible catalysts or pricing power. Low multiples on deteriorating operations often signal value traps rather than bargains, and nothing in the current trajectory suggests that pattern has been broken.
Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Ireland and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
PEERS
Related securities · others in PRGO's space worth a look
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
PRGO trades on the NYSE (the company is based in Ireland). As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16. Entered 2026-07-18 · Distribution
JOURNAL
The dated journal · newest first, never edited
2026-07-18Distribution$10.99+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 57%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (4 analysts) rates it none, with a mean price target of $16.
2026-07-03Distribution$10.99+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$10.99Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
RETURNS
What holding actually paid · price plus dividends
If $1,000 had been placed · historical, not a promise
Period
Price then
Price return
Divs per share
$1,000 became
Total return
1 month
$10.79
+4.7%
$0.29
$1,074
+7.4%
2 months
$10.58
+6.7%
$0.29
$1,094
+9.4%
3 months
$9.18
+23.0%
$0.29
$1,262
+26.2%
6 months
$12.80
-11.8%
$0.58
$928
-7.2%
1 year
$25.99
-56.5%
$0.87
$468
-53.2%
2 years
$24.66
-54.2%
$2.00
$539
-46.1%
3 years
$29.13
-61.2%
$3.10
$494
-50.6%
5 years
$39.29
-71.3%
$5.17
$419
-58.1%
Historical returns from market close data. Past performance does not guarantee future results.
SEALED
This entry now belongs to the ledger. Whatever PRGO does next, these words stay.
Perrigo Company plc · PRGO · Distribution · $10.72
Recorded 2026-07-19 · before the outcome · scored mechanically
